We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer.
- Authors
Hae Su Kim; Ji Yun Lee; Ho Yeong Lim; Hyun Hwan Sung; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han-Yong Choi; Se Hoon Park; Kim, Hae Su; Lee, Ji Yun; Lee, Su Jin; Lim, Ho Yeong; Sung, Hyun Hwan; Jeon, Hwang Gyun; Jeong, Byong Chang; Seo, Seong Il; Jeon, Seong Soo
- Abstract
<bold>Background: </bold>The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC).<bold>Methods: </bold>We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m2 on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m2 every 3 weeks for patients with CRPC (n = 24). After Oct 2013, all chemotherapy-naïve patients with CRPC received a 40 mg/m2 biweekly regimen (n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline.<bold>Results: </bold>The baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups.<bold>Conclusions: </bold>Within the limitations of a retrospective study, the biweekly reduced dose docetaxel regimen was active and well-tolerated in Korean patients with metastatic CRPC.
- Subjects
FEASIBILITY studies; DOCETAXEL; CASTRATION; PROSTATE cancer treatment; CANCER chemotherapy; ANTINEOPLASTIC agents; ASIANS; DRUG administration; HYDROCARBONS; METASTASIS; PROSTATE tumors; PILOT projects; TREATMENT effectiveness; RETROSPECTIVE studies
- Publication
BMC Urology, 2017, Vol 17, p1
- ISSN
1471-2490
- Publication type
journal article
- DOI
10.1186/s12894-017-0253-z